Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.
In a new article published in Nature Chemistry, Moffitt Cancer Center researchers describe their development of a new reagent that allows a more efficient approach to make sulfoximines, sulfonimidoyl fluorides and sulfonimidamides that may be used in medicines.
20221027104337.jpg&width=400&height=400)
Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium as well as the ASCO Genitourinary Cancers Symposium this month.
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.
UC Davis Health and Kaiser Permanente Division of Research received a $24 million grant from the National Institute on Aging, part of the NIH, to continue the Study of Healthy Aging in African Americans (STAR).
Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy, or death by 60% compared to standard therapy. Despite these positive outcomes in event-free survival and overall survival, some patients did not respond well to therapy or relapsed quickly after treatment. Researchers wanted to assess if there were specific tumor characteristics associated with improved outcomes that could better inform treatment selection. Their findings were published today in Nature Medicine.
In a recent article published in Nature Communications, Moffitt Cancer Center researchers, in collaboration with The Tisch Cancer Institute; St. Jude Children’s Research Hospital; the Agency for Science, Technology and Research in Singapore; and the University of Otago in New Zealand, demonstrate that deregulation of a protein called RBFOX2, involved in RNA splicing, contributes to the progression and metastasis of pancreatic cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include insights into the effects of the gut microbiome on remote tumors, a screening strategy for ovarian cancer early detection, a combination approach to overcome PARP inhibitor resistance, further understanding of ferroptosis resistance, a ferroptosis-based strategy for overcoming treatment resistance in acute myeloid leukemia (AML), potential targets for p53 mutations that lead to cancer progression, a signature for more accurately predicting risk in patients with AML given low-intensity treatments, and a prognostic tool to stratify patients with colorectal cancer.
Researchers at Dana-Farber Cancer Institute and the University of Trento, Italy, have developed a blood test, described in Cancer Discovery, that can reliably detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate cancer-adenocarcinoma.
While scientists have made significant progress in understanding the molecular mechanisms leading to melanoma development, it is still unclear how the PTEN protein regulates melanoma progression. In a new study published in Cancer Research, a journal of the American Association for Cancer Research, Moffitt Cancer Center researchers reveal how the antitumor activity of PTEN suppresses the cancer-promoting activity of the FRA1 transcription factor through the AKT signaling pathway.
A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.
For the first time ever in New Mexico, doctors at UNM Comprehensive Cancer Center have treated blood cancer patients by transplanting cells from a donor. Late last year, Matthew Fero, MD, FACP, and the Stem Cell and Bone Marrow Transplant team completed the first procedure, known as an allogeneic stem cell transplant.
Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a $500,000 collaborative grant from Gabrielle's Angel Foundation for Cancer Research and The Mark Foundation for Cancer Research.
In a new case study published in New England Journal of Medicine Catalyst’s January 2024 issue, UC Davis Health shared a road map for increasing workforce diversity across the health care industry.
• Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters
High levels of folic acid or vitamin B12 deficiency can affect fetal brain development in mice, according to a new study from researchers at the University of California, Davis.
A new study shows COVID-19 is not linked to long-term loss of kidney function, despite many patients hospitalized with the -19 virus who experienced acute kidney injury.
A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.
In an NIH-funded study, UC Davis pulmonology researchers are exploring whether delivering statins by inhalation can lead to better outcomes for people with asthma.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers in the United States—is celebrating six years of working alongside the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI), as part of Allied Against Cancer.
Dozens of eye drop recalls this year have left consumers confused about product safety. An expert explains why there have been so many recalls and how to pick safe eye drops.
Nearly two in five U.S. adults have high cholesterol, according to the Centers for Disease Control and Prevention (CDC).
The Cancer Research Institute and Lance Kawaguchi with the #SouthPoleTrek4Cancer ring in the Nasdaq Stock Market Closing Bell.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects to evaluate the effectiveness of elranatamab in the treatment of multiple myeloma.
Nidhi Sahni, Ph.D., associate professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been awarded the 2024 Mary Beth Maddox Award and Lectureship in cancer research from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).
The University of New Mexico Comprehensive Cancer Center is expanding its clinical space to offer treatments that no other entity in the state can offer.
Moffitt Cancer Center researchers are working to better understand the molecular mechanisms that promote the development and progression of breast cancer brain metastasis to help improve diagnostics and treatments. In a new study published in the December issue of Cell Reports, they report on identifying a cell signaling pathway that controls breast cancer brain metastasis.
UC Davis researchers are recruiting infants ages 6-12 months for a new national telehealth study aimed at understanding which developmental delays could indicate autism or other conditions.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
Memorial Sloan Kettering Cancer Center (MSK) today announced the largest single donation in its nearly 150-year history, a $400 million gift from Kenneth C. Griffin, Founder and Chief Executive Officer of Citadel and Founder of Griffin Catalyst, and David Geffen, Founder of The David Geffen Foundation.
New research results in JNCCN are encouraging regarding the benefit of immunotherapy for treating lung cancer across racial and ethnic groups, but also reinforce need to include more Black and Hispanic people in cancer clinical trials and highlight the importance of equitable treatment delivery for closing disparities in outcomes.
A study in Psychology of Addictive Behaviors finds teens who have more demand for cannabis are likely to use it for enjoyment and coping. Understanding motives is important for addiction prevention.
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis.
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
MD Anderson and Rigel Pharmaceuticals announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia and other hematologic cancers.
The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
CRI's 2023 Patient Immunotherapy Summit is now available on-demand for the benefit of cancer patients, families, caregivers, and scientists.
Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.
In a new study published in the Journal for ImmunoTherapy of Cancer, a team of researchers from the Donald A. Adam Melanoma and Skin Cancer Center of Excellence at Moffitt Cancer Center reveals differences in the mechanisms of action of two FDA-approved immune checkpoint inhibitor combination therapies for advanced melanoma.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
NCCN—an alliance of leading cancer centers—hosted a Patient Advocacy Summit to explore the role of navigation throughout the cancer process. A diverse group of subject matter experts addressed the impact patient navigation has on care and how to utilize navigators to reduce economic burdens and disparities in care.
Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York State’s first cell therapy manufacturing and research hub. Brian Betts, MD, has joined Roswell Park as Vice Chair of Strategic Initiatives within the Transplant & Cellular Therapy Section, Department of Medicine; Kanwaldeep Mallhi, MD, was named Associate Professor of Oncology and Clinical Director of Pediatric Transplantation and Cellular Therapy in the Department of Pediatrics; and Shernan Holtan, MD, will join the Roswell Park faculty in February as Chief of Blood and Marrow Transplant in the Department of Medicine.
Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells. The efficacy of T-DXd and SG depends on target expression and the best method for measuring that expression is still not known.
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center, has been honored with the E. Donnall Thomas Lecture and Prize from the American Society of Hematology (ASH, for her groundbreaking research to develop and advance innovative cell therapies for cancer using natural killer (NK) cells.
Based on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.
Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right